Slide 1: Third Quarter 2008 Webcast
Exhibit 99.1 Third Quarter 2008 Webcast October 23, 2008
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation, made on October 23, 2008, includes forward-looking statements based on current expectations and Alcon does not undertake the obligation to update the forward-looking information or statements. These expectations could differ materially from actual results and
Slide 3: Business Overview
Business Overview Cary Rayment Chairman, President & CEO
Slide 4: Third Quarter Sales Highlights
Third Quarter Sales Highlights 3rd Qtr September 2008 YTD (dollars in millions) (dollars in millions) $1,700 $5,200 . 1 % 10.3% $5,000 . 1 % 10.3% +14 cy* +16 cy* $1,600 + + e n e n Curr $4,800 Curr $1,500 t t stan $1,524.6 stan $4,796.2 n n Co $4,600 Co $1,400 $4,400 $1,300 $1,335.7 $4,200 $1,200 $
Slide 5: Q3 2008 Geographic Sales and Growth
Q3 2008 Geographic Sales and Growth Q3 2008 Sales by Geography $298.9 Reported: +27.8% Constant Currency*: +19.8% Emerging Markets $681.3 19.6% Reported: +4.1% U.S. 44.7% Developed International 35.7% $544.4 Reported: +21.7% Constant Currency*: +14.3% (dollars in millions) * Constant currency sales
Slide 6: Pharmaceutical Sales
Pharmaceutical Sales Q3 2008 Sales by Product Line 3rd Qtr (dollars in millions) $700 Consumer $223.7 1. 4% y* +7.8% 14.7% $650 +1 nc urr e nt C Pharma a o nst $609.6 $600 C $609.6 40.0% Surgical $550 $691.3 45.3% $547.3 $500 (dollars in millions) $450 Q3 2007 Q3 2008 * Constant currency sales growt
Slide 7: Gaining Market Share in Pharmaceuticals
Gaining Market Share in Pharmaceuticals Global US US RX Growth June YTD August YTD August 2008 Brand Market Brand Market Market TRAVATAN® Family 16.3% 8.3% 12.4% -1.2% -6.7% Azopt® 7.7% 6.1% 16.6% 4.3% -5.1% Vigamox® * 20.6% 7.7% -2.5% -4.6% -11.1% TobraDex® 6.8% 7.4% -8.3% -4.7% -10.9% NEVANAC® 62.
Slide 8: Alcon Glaucoma Strength
Alcon Glaucoma Strength U.S. Rx Share of TRAVATAN Z® as a Alcon Global Prostaglandin Market Share Percentage of the Total TRAVATAN® Franchise TRAVATAN® Family revenues TRAVATAN® Franchise is up 6.3 share up 20.2% for Q3 2008 points since TRAVATAN Z® launch 20% 18.4% 100% 16% 14.6% TRAVATAN® 12% 55%
Slide 9: Strong Share Gains from Azopt
Strong Share Gains from Azopt® Global TCAI Market Share Development 60% Azopt® revenues up 19.9% for Q3 2008 55.9% Azopt ® Trusopt * 55% 49.5% 14.2 Share 50% Point Spread 48.8% 45% 41.7% 40% Q3 06 Q4 06 Q1 07 Q2 07 Q3 07 Q4 07 Q1 08 Q2 08 Source: IMS * Trusopt is a registered trademark of Merck.
Slide 10: Surgical Sales
Surgical Sales Q3 2008 Sales by Product Line 3rd Qtr (dollars in millions) $800 Consumer $223.7 $750 0 % .7% 8. ncy* + 1 3 14.7% Pharma 1 + urre $609.6 $700 C ta nt ns 40.0% Co $691.3 $650 Surgical $600 $691.3 $550 $585.9 45.3% $500 (dollars in millions) Q3 2007 Q3 2008 * Constant currency sales gro
Slide 11: Alcon Monofocal IOLs are Growing Share
Alcon Monofocal IOLs are Growing Share U.S. Monofocal IOL Market Shares 70% 64.3% 60.3% 61.6% 58.8% 60% 50% 40% 30% 20% 10% 0% FY 2005 FY 2006 FY 2007 Q2 YTD 2008 Source: Market Scope ACL B&L AMO
Slide 12: Advanced Technology IOL Sales Trend
Advanced Technology IOL Sales Trend $60 $50.0 $50 $40 (dollars in millions) $30 $20 $10 $- Q1 05 Q2 05 Q3 05 Q4 05 Q1 06 Q2 06 Q3 06 Q4 06 Q1 07 Q2 07 Q3 07 Q4 07 Q1 08 Q2 08 Q3 08 ReSTOR® ReSTOR® CMS Source: Company Analysis Toric Toric CMS ReSTOR® Launch Decision Launch Decision Aspheric Launch
Slide 13: Cataract Procedure and Viscoelastic Share Growth
Cataract Procedure and Viscoelastic Share Growth U.S. Phaco Machine Share U.S. Viscoelastics Share 80% 80% 65.6% 65.3% 70% 70% 59.6% 58.9% 60% 60% 50% 50% 40% 40% 30% 30% 20% 20% 10% 10% 0% 0% FY 2005 FY 2006 FY 2007 YTD Q2 FY 2005 FY 2006 FY 2007 YTD Q2 2008 2008 Source: Market Scope Source: Market
Slide 14: Consumer Sales
Consumer Sales Q3 2008 Sales by Product Line 3rd Qtr (dollars in millions) $300 Consumer $223.7 14.7% 0. 5% y* +7.0% $250 +1 nc urr e Pharma t a nt C ns $609.6 Co 40.0% $223.7 Surgical $200 $691.3 $202.5 45.3% $150 (dollars in millions) Q3 2007 Q3 2008 * Constant currency sales growth is a non-GAAP
Slide 15: Contact Lens Care Market Share Success
Contact Lens Care Market Share Success U.S. Contact Lens Care Market Share (including Private Label) 45 38.7% 40 35 (shares by percentage) 30 25 20 15 10 5 0 Dec-07 Jan-08 Feb-08 Mar-08 Apr-08 May-08 Jun-08 Jul-08 Aug-08 Sep-08 Oct-08 Source: Nielsen Alcon B&L AMO CIBA Private Label
Slide 16: Impact of Systane on Dry Eye Revenue
Impact of Systane® on Dry Eye Revenue Global Dollar Sales by Quarter of Dry Eye Products $80 $73.2 Alcon #2 in Dry Eye in the U.S. $70 with a 24.3 market share $60 (dollars in millions) $50 $40 $30 $20 $10 $0 1Q2003 1Q2004 1Q2005 1Q2006 1Q2007 1Q2008 Source: Company Figures Tears Naturale ® Other Sy
Slide 17: Financial Review
Financial Review Rick Croarkin Senior Vice President, Finance and Chief Financial Officer
Slide 18: Q3 Gross Profit
Q3 Gross Profit 3rd Qtr September 2008 YTD $1,300 (dollars in millions) $4,000 (dollars in millions) +16.3% $3,800 +17.1% $1,200 $3,600 $1,176.2 $3,635.0 $1,100 $3,400 $3,200 $1,000 $1,011.1 $3,000 $3,103.0 $900 $2,800 Q3 2007 Q3 2008 Sept YTD 2007 Sept YTD 2008 % of % of 75.7% 77.1% 75.1% 75.8% Sal
Slide 19: Q3 Operating Profit
Q3 Operating Profit 3rd Qtr September 2008 YTD $550 (dollars in millions) $1,800 (dollars in millions) +6.1% +16.7% $494.3 $1,600 $1,640.0 $450 $466.1 $1,400 $1,405.7 $350 $1,200 Q3 2007 Q3 2008 Sept YTD 2007 Sept YTD 2008 % of % of 34.9% 32.4% 34.0% 34.2% Sales Sales
Slide 20: Q3 Net Earnings
Q3 Net Earnings 3rd Qtr September 2008 YTD $700 (dollars in millions) $1,800 (dollars in millions) +51.0% +34.1% $600 $1,600 $627.1 $1,622.9 $500 $1,400 $400 $1,200 $415.3 $1,209.9 $300 $1,000 Q3 2007 Q3 2008 Sept YTD 2007 Sept YTD 2008 % of % of 31.1% 41.1% 29.3% 33.8% Sales Sales
Slide 21: Alcon Investment Portfolio Allocation
Alcon Investment Portfolio Allocation Investment Allocation at Q3 2008 $3.12 Billion Portfolio REITs 0.9% Fixed Income 5.6% Hedge Funds 4.8% Bank Loans 4.6% Equities Cash 0.9% 83.2%
Slide 22: Alcon Historical Investment Performance
Alcon Historical Investment Performance FY FY FY FY Q1 Q2 Q3 YTD (dollars in millions) 2004 2005 2006 2007 2008 2008 2008 2008 Interest Income $23.3 $48.7 $74.1 $69.3 $25.7 $20.5 $19.8 $66.0 Investment/ ($ 0.3) $ 4.4 $21.2 $15.4 ($11.7) $ 0.5 ($43.2) ($54.4) Other Net Investment $23.0 $53.1 $95.3 $8
Slide 23: Q3 Income Taxes
Q3 Income Taxes • $239.5 million Summit Autonomous tax benefit resulted in total tax benefit of $177.6 million • Taxes on operations totaled $61.9 million • Shared Service Center tax benefit reduced the overall tax rate • YTD Q3 2008 tax rate was 13.7% excluding the Summit Autonomous tax benefit vs.
Slide 24: Q3 Diluted EPS
Q3 Diluted EPS 3rd Qtr September 2008 YTD $2.50 $6.00 +50.0% +34.5% $2.25 $5.50 $2.00 $5.38 $2.07 $5.00 $1.75 $4.50 $1.50 $1.38 $4.00 $1.25 $4.00 $1.00 $3.50 Q3 2007 Q3 2008 Sept YTD 2007 Sept YTD 2008
Slide 25: 2008 Full Year Financial Guidance Revision
2008 Full Year Financial Guidance Revision • Sales range of $6,260 to $6,290 million • Diluted earnings per share range of $6.67 to $6.75 • The guidance includes: • Summit Autonomous tax benefits • Benefits from the R&D tax credit • Tax savings and costs to establish Shared Service Centers • Integra
Slide 26: Slide 26
Slide 27: Non-GAAP Constant Currency Reconciliation
Non-GAAP Constant Currency Reconciliation Q3 Constant Q3 GAAP Exchange (dollars in millions) Currency Growth Rate Rate Changes Growth Rate Global Sales 14.1% (3.8) 10.3% Pharmaceutical 11.4% (3.6) 7.8% Surgical 18.0 (4.3) 13.7 Consumer 10.5 (3.5) 7.0 United States 4.1% -- 4.1% Developed Internationa